Akthelia Pharmaceuticals

Akthelia Pharmaceuticals is an emerging company dedicated to the discovery and development of novel antimicrobial therapeutics aimed at enhancing the body's innate microbial defenses. With rising antibiotic resistance posing significant healthcare challenges, Akthelia focuses on creating new anti-infective agents effective against drug-resistant bacteria and opportunistic infections. The company has a diverse pipeline targeting lung and gastrointestinal infections, developed in collaboration with researchers from the Karolinska Institute in Stockholm and the University of Iceland. Akthelia's innovative approach involves stimulating the production of naturally occurring antimicrobial peptides, which enables its drugs to effectively combat various bacterial strains, including those resistant to existing antibiotics. This research-driven strategy fosters the generation of new product opportunities, addressing critical needs in infection management and wound healing.